No Data
No Data
Inozyme Pharma Initiated at Overweight by Wells Fargo
Inozyme Pharma Initiated at Overweight by Wells Fargo
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
Express News | Inozyme Pharma Inc : Wells Fargo Initiates Coverage With Overweight Rating; Target Price $14
Express News | Inozyme Pharma To Present Phase 1/2 Trial Data Of INZ-701 In Adults With ENPP1 Deficiency And ABCC6 Deficiency
Inozyme Pharma to Present Recently Announced Data From Phase 1/2 Trials of INZ-701 in Adults With ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of
No Data